Intervene Immune
Manhattan Beach, US · Nevada corporation
Intervene Immune develops treatments aimed at rejuvenating the immune system by regenerating the thymus and reversing biological aging, building on its TRIIM and TRIIM-X clinical trials. The company applies aging biology and epigenetic age measurement to human longevity interventions.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$470.8K disclosed across 1 round · 2013
▶$470.8KraisedDec 2019 · 6 investors · BiotechnologyRule 506(b)
▶$470.8KraisedDec 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory FahyExecutive Officer, Director
- Robert BrookeExecutive Officer, Director
- Philip Kernan Jr.Executive Officer, Director
- Paul HynekExecutive Officer
- Amount sold
- $470.8K
- First sale
- Nov 2013
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 04, 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapVerImmune5 shared keywordsVerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
Inimmune4 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Immunomic Therapeutics4 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Companies competing with Intervene Immune for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Intervene Immune do?
- Intervene Immune develops treatments aimed at rejuvenating the immune system by regenerating the thymus and reversing biological aging, building on its TRIIM and TRIIM-X clinical trials. The company applies aging biology and epigenetic age measurement to human longevity interventions.
- Who founded Intervene Immune?
- Intervene Immune was founded by Gregory Fahy, Robert Brooke, Greg Fahy.
- How much funding has Intervene Immune raised?
- Intervene Immune has disclosed $470.8K raised across 1 round.
- Where is Intervene Immune headquartered?
- Intervene Immune is headquartered in Manhattan Beach, US.